The Journal of Gynecological Cancer recently published the meeting report for the 12th Ovarian Cancer Research Symposium. The symposium was organized by the Rivkin Center in partnership with the American Association for Cancer Research (AACR) at the University of Washington Campus in Seattle, WA from September 13-15, 2018. The three-day event brought together a record […]
The Federal Drug Administration (FDA) made an exciting announcement this week with the first approval for PARP inhibitors to be used for patients following their initial diagnosis and treatment to reduce the risk of recurrence. The FDA approved the use of the PARP inhibitor olaparib (Lynparza®) for frontline maintenance therapy for advanced epithelial ovarian, fallopian […]
You may have read in recent news that a new research study found that daily, low-dose aspirin may lower a woman’s risk of developing ovarian cancer. So does that mean you should start — or change — your aspirin regimen? Dr. Nora Disis, our Medical and Scientific Director and the Director of the University of […]
As one of the largest private funders of ovarian cancer research, we’re excited to announce the awardees of this year’s pilot and scholar research grants. Over 170 applications poured in from around the world. Fourteen were chosen. Why is funding scientific research important? Ovarian cancer kills more than 22,000 women every year in the United […]
Dr. Rivkin and I attended the annual meeting of the American Society of Clinical Oncology (ASCO)—a gathering of 38,000 oncology experts from all over the world—in early June in Chicago, Illinois. In addition to oncologists, the attendees included researchers, educators, advocates, research funders, survivors and representatives from genetic testing, drug and other services companies. Our […]
A study published in Lancet Oncology by Dr. Iain McNeish (2016 Rivkin Pilot Award Recipient), Dr. Elizabeth Swisher (2009 Rivkin Pilot Award Recipient), and colleagues provided key data that helped fuel the FDA’s recent approval of rucaparib for ovarian cancers with defects in the BRCA1 and BRCA2 genes in women previously treated with two or more chemotherapies.